List of Excipients in Branded Drug GRANISETRON

Generic Drugs Containing GRANISETRON

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	granisetron hydrochloride	63323-319	CITRIC ACID MONOHYDRATE
Fresenius Kabi USA LLC	granisetron hydrochloride	63323-319	PHENOL
Fresenius Kabi USA LLC	granisetron hydrochloride	63323-319	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in GRANISETRON?

# Of NDCs	Excipient
1	CITRIC ACID MONOHYDRATE
1	PHENOL
1	SODIUM CHLORIDE

Granisetron Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Granisetron is a mature 5-HT3 receptor antagonist with limited opportunity in conventional immediate-release tablets and injections. The strongest commercial opportunities are differentiated delivery systems: transdermal systems, extended-release subcutaneous injections, orally disintegrating or taste-masked products, preservative-free parenterals, and formulations that improve adherence during multi-day chemotherapy.

The core product is granisetron hydrochloride, marketed in oral and injectable forms. Sancuso is a granisetron transdermal patch, while Sustol is an extended-release subcutaneous injection. These products demonstrate that commercial value depends less on the active ingredient and more on delivery, exposure control, administration setting, and protection of formulation know-how.

What formulations contain granisetron?

Granisetron is available in several dosage forms with distinct excipient requirements.

Dosage form	Representative product	Administration	Commercial role	Primary excipient priorities
Immediate-release tablet	Generic granisetron tablets, Kytril legacy product	Oral	Low-cost acute or scheduled prophylaxis	Disintegration, compression, stability, low manufacturing cost
Oral solution	Generic or institutional products	Oral	Patients unable to swallow tablets	Solubility, taste masking, preservative system, microbial control
Injection	Generic granisetron hydrochloride injection	Intravenous	Hospital and infusion-center use	Sterility, pH, tonicity, low particulate burden, container compatibility
Transdermal system	Sancuso	Topical, multi-day delivery	Patients receiving multi-day chemotherapy	Adhesion, drug flux, skin tolerability, residual drug control
Extended-release subcutaneous injection	Sustol	Subcutaneous	Delayed and extended prophylaxis for chemotherapy-induced nausea and vomiting	Suspension stability, syringeability, depot release, local tolerability
Orally disintegrating tablet or film	Development opportunity	Oral	Patients with swallowing difficulty or treatment-related nausea	Rapid wetting, taste masking, friability, dose uniformity

Granisetron hydrochloride is water soluble enough for conventional parenteral development, but its formulation must control pH, ionic strength, oxidation risk, container interactions, and sterilization compatibility. Oral formulations require less complex chemistry but face price competition and limited patent differentiation.

What excipients are used in granisetron tablets and injections?

Exact excipient compositions vary by manufacturer and strength. Common excipient classes include fillers, binders, disintegrants, lubricants, film-forming polymers, buffering agents, tonicity agents, and preservatives.

Immediate-release tablets

A conventional granisetron tablet may use:

• Lactose, mannitol, or microcrystalline cellulose as a diluent
• Povidone or copovidone as a binder
• Croscarmellose sodium, crospovidone, or sodium starch glycolate as a disintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Hypromellose, titanium dioxide, polyethylene glycol, and iron oxides in a film coat

The preferred strategy is a low-cost, robust direct-compression or dry-granulation platform. Since the dose is small, content uniformity is more important than bulk drug loading. Granisetron’s narrow product differentiation makes manufacturing yield, tablet robustness, and supply-chain cost central commercial variables.

Excipient selection should avoid unnecessary complexity. A novel excipient system rarely creates meaningful market protection for a standard tablet unless it produces a measurable advantage such as improved disintegration, lower friability, better stability, or a regulatory pathway for a differentiated dosage form.

Oral liquids

An oral liquid requires a different strategy. Granisetron hydrochloride can be formulated as a solution or suspension, but palatability is a major development constraint.

Relevant excipients include:

• Purified water as the vehicle
• Citrate or phosphate buffers
• Glycerin, sorbitol, or propylene glycol as cosolvents or humectants
• Sucralose, saccharin, or other sweeteners
• Flavor systems
• Polysorbates or other wetting agents where needed
• Preservatives such as parabens or benzoate systems, subject to compatibility and patient-population requirements
• Suspending agents such as xanthan gum or cellulose derivatives when a suspension is used

The commercial opportunity is strongest where patients cannot reliably swallow tablets, including oncology patients, pediatric patients, and patients with mucositis or severe nausea. A preservative-free unit-dose liquid could also target hospital and ambulatory infusion settings, although container cost and microbial-control requirements would reduce margin.

Injectable products

Granisetron injection is generally formulated around:

• Water for injection
• A pH-adjusting or buffering system
• Sodium chloride or another tonicity agent
• A suitable container closure system
• Preservative or preservative-free presentation, depending on product design

The key technical risks are precipitation, pH drift, adsorption to container surfaces, extractables and leachables, visible and subvisible particles, and stability after dilution into infusion fluids.

A commercially attractive injectable product would focus on operational efficiency rather than a new excipient alone. Examples include a ready-to-administer prefilled syringe, a premixed infusion bag, a preservative-free single-dose vial, or a presentation with a longer in-use period after opening or dilution.

What excipient strategies can differentiate granisetron?

The highest-value strategies link excipient choice to a defined clinical or operational problem.

Taste masking for oral and pediatric products

Taste masking can support an orally disintegrating tablet, oral granules, chewable tablet, or oral film. Granisetron’s low dose makes ion-exchange resins, polymeric coatings, lipid barriers, and multiparticulate systems technically feasible.

A practical approach is to combine:

1. Drug-resin complexation or coated granules.
2. A rapidly wetting carrier such as mannitol.
3. A high-intensity sweetener and flavor system.
4. A low-moisture packaging configuration.

The product must release granisetron rapidly after swallowing while minimizing drug release in the mouth. The key development tests are dissolution across pH, sensory performance, dose uniformity, moisture uptake, and stability after opening.

Orally disintegrating tablets

An orally disintegrating granisetron product could target patients who experience nausea before or during oral dosing. Excipients such as mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and colloidal silicon dioxide can support rapid breakup and acceptable mouthfeel.

The commercial challenge is bioequivalence. A product that disintegrates in the mouth but is swallowed with saliva may still qualify as an immediate-release oral product, but the formulation must meet applicable FDA bioequivalence requirements. A true clinical advantage requires faster onset, better adherence, or use in patients who cannot swallow conventional tablets.

Transdermal delivery

Sancuso demonstrates the commercial value of multi-day transdermal granisetron delivery. The patch uses a drug-in-adhesive approach and delivers granisetron over several days for chemotherapy-induced nausea and vomiting. The label identifies a delivery rate of approximately 3.1 mg per 24 hours and a total drug content substantially higher than the delivered dose, reflecting the need to maintain a concentration gradient across the skin (U.S. Food and Drug Administration, 2023a).

The critical excipient and material considerations are:

• Acrylic or other pressure-sensitive adhesive selection
• Skin permeation enhancement
• Drug crystallization control
• Backing-film and release-liner compatibility
• Adhesion under sweating and movement
• Low skin irritation and sensitization
• Residual drug after removal
• Packaging protection from heat and moisture

A generic or follow-on patch would face a higher technical barrier than a tablet. FDA approval would require comparative adhesion, residual drug, irritation, pharmacokinetic, and quality data. The patch also creates device and combination-product requirements that can slow development.

Extended-release subcutaneous injection

Sustol uses an extended-release subcutaneous delivery system for granisetron. The product is designed to release drug over an extended period rather than provide a short intravenous or subcutaneous exposure. Such a system can reduce the need for repeated dosing during chemotherapy cycles (U.S. Food and Drug Administration, 2023b).

An alternative depot strategy could use:

• Biodegradable polyesters such as PLGA
• Lipid-based depots
• In situ forming implants
• Suspensions with controlled particle size
• Viscosity modifiers and surfactants
• Buffer systems that limit local pH changes

The primary risks are syringeability, needle size, depot reproducibility, injection-site reactions, burst release, and incomplete dose delivery. An excipient platform that produces less pain or a smaller injection volume could have commercial value even if systemic efficacy is similar.

When does granisetron lose exclusivity?

The original granisetron small-molecule exclusivity period has expired. Conventional oral tablets and immediate-release injections are generic products, and no active biosimilar pathway applies because granisetron is a chemically synthesized small molecule rather than a biologic.

Product category	Regulatory position	Exclusivity assessment
Conventional granisetron tablets	Generic small-molecule product	Original innovator exclusivity expired
Immediate-release granisetron injection	Generic small-molecule product	Original innovator exclusivity expired
Sancuso transdermal system	Branded drug-device combination	Product-specific patents and regulatory protections govern competition
Sustol extended-release injection	Branded extended-release injectable	Product-specific formulation and delivery claims govern competition
New oral film, ODT, liquid, or depot	Potential 505(b)(2) or ANDA product, depending on design	New formulation patents and regulatory exclusivity may be available

For mature granisetron products, the relevant question is not when granisetron itself loses exclusivity. It is whether a particular delivery system remains protected by unexpired patents, regulatory exclusivity, contractual restrictions, manufacturing know-how, or technical barriers.

What is the Orange Book status of granisetron products?

The FDA Orange Book lists approved drug products, therapeutic equivalence evaluations, patents submitted by sponsors, and certain exclusivity information. Conventional granisetron tablets and injections have generic competition and are generally evaluated through abbreviated new drug applications.

Sancuso and Sustol require separate analysis because the products use differentiated delivery systems. Orange Book-listed patents may cover the drug, dosage form, method of use, delivery profile, device, or formulation. A listed patent does not itself establish that every claim is valid or infringed. It does, however, affect ANDA certification and potential Paragraph IV litigation under the Hatch-Waxman framework (U.S. Food and Drug Administration, 2023c).

Patent analysis should separate:

• Active pharmaceutical ingredient claims
• Salt and polymorph claims
• Transdermal matrix and adhesive claims
• Extended-release depot claims
• Device and container claims
• Method-of-use claims for chemotherapy regimens
• Manufacturing and process claims

No biosimilar litigation is relevant to granisetron. Competition is based on generic, follow-on formulation, 505(b)(2), and drug-device pathways.

Which companies are challenging granisetron products?

Generic manufacturers have challenged and commercialized conventional oral and injectable granisetron products. The competitive field includes established generic manufacturers and contract manufacturing organizations with sterile injectable capacity.

The more difficult targets are Sancuso and Sustol. Competition against these products is likely to depend on:

• Whether a listed patent blocks an ANDA or 505(b)(2) pathway
• Whether the proposed product uses the same delivery mechanism
• Whether the applicant can establish bioequivalence or clinical bridging
• Whether device performance is part of the FDA review
• Whether a Paragraph IV certification triggers litigation
• Whether a settlement delays launch or permits an authorized generic

Publicly reported litigation and settlement positions must be assessed product by product. There is no single patent challenge applicable to all granisetron presentations.

What patent litigation affects granisetron?

The main litigation exposure is concentrated in differentiated products rather than conventional granisetron tablets.

Sancuso

Potential dispute areas include:

• Adhesive matrix composition
• Transdermal delivery rate
• Patch construction
• Drug loading and release behavior
• Use during multi-day chemotherapy
• Combination of granisetron with backing and liner materials

Sustol

Potential dispute areas include:

• Extended-release subcutaneous formulation
• Depot-forming excipients
• Drug particle engineering
• Release kinetics
• Injection device or presentation
• Use for delayed and acute chemotherapy-induced nausea and vomiting

A Paragraph IV applicant may challenge validity, enforceability, or infringement. A non-infringing design could avoid some claims but may require a different formulation, delivery platform, or dosing regimen. For investors and licensees, freedom-to-operate work should examine issued claims, pending continuations, terminal disclaimers, prosecution history, and foreign counterparts.

What generic entry risks exist for granisetron?

Generic entry risk is high for conventional granisetron tablets and injections because:

• The active ingredient is established.
• Clinical experience is extensive.
• Manufacturing processes are familiar.
• The products have low technical complexity.
• Multiple suppliers can produce the dosage forms.
• Price competition is established.

Entry risk is lower for transdermal and extended-release products. These products require more development capital, specialized manufacturing, device testing, and regulatory work. Their protection can also extend beyond a single patent through a layered estate covering formulation, process, device, and use.

The highest-risk scenario for a branded differentiated product is a follow-on product that matches the delivery profile while avoiding key formulation claims. The lowest-risk scenario is a conventional generic that competes only in the tablet or immediate-release injection market.

How strong is the granisetron patent estate?

The granisetron API estate is weak because the molecule is mature and genericized. The formulation estate is more variable.

Patent layer	Relative strength	Reason
Original compound patents	Low	Historical rights have expired
Conventional tablet formulation	Low	Easy design-around and established generic technology
Immediate-release injection	Low to moderate	Sterile manufacturing adds operational barriers, but formulation claims may be narrow
Transdermal patch	Moderate to strong	Adhesion, flux, construction, and device claims can create multiple barriers
Extended-release subcutaneous depot	Moderate to strong	Complex release technology and manufacturing know-how
Method-of-use claims	Variable	Depend on claim scope, prior art, and the approved labeling
Manufacturing-process claims	Moderate	Can be valuable if difficult to reproduce, but may be avoided through alternate processes

The most durable commercial protection is usually a combination of patents and know-how. A patent covering a specific polymer or adhesive may be designed around, while validated process parameters, drug loading controls, and device assembly methods can remain difficult to replicate.

What are the commercial opportunities for granisetron excipients?

1. Hospital-ready injectable products

A ready-to-use syringe or premixed bag could reduce preparation time and dosing errors. The value proposition is operational rather than pharmacologic. Excipients should support long shelf life, low particulate levels, container compatibility, and rapid administration.

2. Pediatric and dysphagia-friendly oral products

Taste-masked granules, ODTs, oral films, and low-volume liquids could expand use in pediatric oncology and patients with swallowing difficulty. Packaging should support unit-dose administration and moisture protection.

3. Preservative-free presentations

Preservative-free single-dose vials and prefilled syringes could target hospitals seeking simplified sterile-product handling. The commercial benefit depends on procurement pricing and whether the presentation reduces waste.

4. Follow-on transdermal systems

A lower-cost patch could compete with Sancuso, but development requires adhesive, skin-permeation, device, and pharmacokinetic expertise. A licensee with existing transdermal manufacturing infrastructure would have a stronger entry position than a conventional generic company.

5. Long-acting depot products

A lower-volume or less painful extended-release injection could compete with Sustol. The strongest opportunity would combine equivalent protection against acute and delayed nausea with improved injection-site tolerability, reduced handling, or lower administration frequency.

6. Combination antiemetic products

Granisetron could be combined with other antiemetic agents in a fixed-dose product, but regulatory and patent analysis would be complex. The commercial rationale would need to show improved adherence or a meaningful reduction in dosing burden. Formulation work would focus on chemical compatibility, release timing, and dose flexibility.

How does granisetron compare with competing 5-HT3 antagonists?

Drug	Common differentiated attributes	Excipient opportunity
Granisetron	Tablet, injection, transdermal patch, extended-release injection	Strongest opportunity in delivery systems
Ondansetron	Broad oral, ODT, liquid, and injectable use	Crowded generic market; taste masking and hospital formats remain possible
Palonosetron	Long half-life and acute/delayed CINV positioning	Less need for repeated dosing; formulation differentiation is more difficult
Dolasetron	Historical 5-HT3 product with reduced current commercial relevance	Limited opportunity
Tropisetron	Used in selected markets	Geographic and regulatory opportunity depends on local approvals

Granisetron’s main advantage for formulation developers is the existence of proven multi-day delivery concepts. Its disadvantage is intense generic competition in standard presentations.

What geographic opportunities exist?

The United States offers the largest opportunity for differentiated products but has the highest regulatory and patent scrutiny. Europe and Japan may offer opportunities for transdermal or depot products where reimbursement favors reduced administration burden. Emerging markets may favor stable oral liquids, low-cost tablets, and ready-to-use injections.

Geographic strategy should account for:

• Local approval of Sancuso or Sustol equivalents
• National patent term and supplementary protection rights
• Hospital procurement practices
• Availability of sterile manufacturing
• Cold-chain and temperature-excursion requirements
• Local demand for pediatric dosage forms
• Reimbursement for transdermal and extended-release products

Manufacturing barriers are highest for sterile injectables, transdermal systems, and controlled-release depots. Excipients alone are unlikely to create durable protection unless integrated into a validated product and manufacturing process.

Key Takeaways

• Conventional granisetron tablets and immediate-release injections are mature generic markets with limited excipient-based differentiation.
• The strongest opportunities are transdermal patches, extended-release subcutaneous injections, ODTs, taste-masked liquids, and hospital-ready sterile products.
• Sancuso and Sustol have higher technical and regulatory barriers than standard granisetron products.
• Granisetron has no biosimilar pathway because it is a small-molecule drug.
• Patent value is concentrated in delivery systems, formulation architecture, manufacturing processes, devices, and method-of-use claims.
• A commercial excipient strategy should solve a measurable problem: adherence, taste, dosing frequency, administration time, stability, injection-site tolerability, or supply-chain cost.
• For licensing, the most valuable partner profiles are transdermal developers, sterile injectable manufacturers, depot-formulation specialists, and companies with established oncology distribution.

FAQs

Can granisetron be formulated as an orally disintegrating tablet?

Yes. An ODT could use mannitol, crospovidone, low-substituted hydroxypropyl cellulose, sweeteners, flavors, and taste-masking technology. Bioequivalence and rapid dissolution would be central regulatory requirements.

Which excipient is best for extending granisetron release?

No single excipient is universally optimal. PLGA, lipid depots, coated particles, and in situ forming systems can provide extended release, but the choice depends on injection volume, release duration, local tolerability, and manufacturing process.

Is a granisetron transdermal patch easier to copy than a tablet?

No. A patch requires control of adhesive performance, skin permeation, drug crystallization, residual drug, device construction, and patient adhesion. These requirements make follow-on development more complex than an immediate-release tablet.

Could a preservative-free granisetron injection support premium pricing?

Potentially, but pricing depends on procurement contracts, waste reduction, packaging convenience, and demonstrated operational benefit. Preservative-free status alone may not justify a premium in a highly competitive hospital market.

What is the best licensing opportunity in granisetron?

The strongest licensing candidates are differentiated delivery systems with manufacturing validation and a clear regulatory pathway. Long-acting subcutaneous depots, transdermal systems, and pediatric taste-masked products offer more defensible value than another conventional tablet.

References

1. U.S. Food and Drug Administration. (2023a). Sancuso (granisetron transdermal system) prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (2023b). Sustol (granisetron) extended-release injection prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/

3. U.S. Food and Drug Administration. (2023c). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/

5. National Library of Medicine. (2024). DailyMed: Granisetron hydrochloride drug labels. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

6. National Cancer Institute. (2024). Cancer treatment-related nausea and vomiting. National Institutes of Health. https://www.cancer.gov/about-cancer/treatment/side-effects/nausea-vomiting